Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:NUVL NASDAQ:SPRY NASDAQ:TGTX NASDAQ:TLX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeNUVLNuvalent$73.28-1.9%$78.76$55.53▼$113.51$5.29B1.3539,046 shs180,572 shsSPRYARS Pharmaceuticals$14.36+4.1%$16.82$10.00▼$18.90$1.42B0.91.55 million shs1.35 million shsTGTXTG Therapeutics$28.15+0.8%$34.60$21.11▼$46.48$4.46B1.952.50 million shs871,887 shsTLXTelix Pharmaceuticals$11.02-2.5%$14.78$10.50▼$30.36$3.73BN/A41,475 shs78,232 shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for August 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceNUVLNuvalent-0.45%-2.53%-10.47%+1.37%-0.28%SPRYARS Pharmaceuticals-1.71%-17.23%-23.05%-3.02%-3.16%TGTXTG Therapeutics+0.69%+2.95%-26.35%-18.36%+10.84%TLXTelix Pharmaceuticals-5.04%+4.44%-30.38%-32.17%+1,129,999,900.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationNUVLNuvalent3.1652 of 5 stars4.51.00.00.02.43.30.0SPRYARS Pharmaceuticals2.651 of 5 stars3.60.00.00.02.24.20.6TGTXTG Therapeutics4.3325 of 5 stars3.41.00.03.53.02.51.9TLXTelix PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceNUVLNuvalent 3.08Buy$118.9162.27% UpsideSPRYARS Pharmaceuticals 3.17Buy$31.00115.89% UpsideTGTXTG Therapeutics 2.75Moderate Buy$46.2564.30% UpsideTLXTelix Pharmaceuticals 3.00Buy$22.33102.66% UpsideCurrent Analyst Ratings BreakdownLatest SPRY, TLX, TGTX, and NUVL Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/19/2025NUVLNuvalentPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$112.007/21/2025NUVLNuvalentWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$115.007/10/2025TGTXTG TherapeuticsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold$37.007/9/2025TLXTelix PharmaceuticalsWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform7/3/2025TLXTelix PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$23.006/30/2025NUVLNuvalentThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy6/25/2025NUVLNuvalentRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$105.00 ➝ $112.006/24/2025NUVLNuvalentWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$115.006/24/2025NUVLNuvalentLeerink PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$125.00 ➝ $140.006/24/2025NUVLNuvalentHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$110.00 ➝ $130.006/12/2025TLXTelix PharmaceuticalsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$22.00(Data available from 8/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookNUVLNuvalentN/AN/AN/AN/A$13.03 per shareN/ASPRYARS Pharmaceuticals$89.15M15.92$0.01 per share1,656.77$1.95 per share7.36TGTXTG Therapeutics$329M13.58$0.12 per share231.16$1.74 per share16.18TLXTelix Pharmaceuticals$783.21M4.76$0.11 per share104.21$1.12 per share9.84Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateNUVLNuvalent-$260.76M-$4.90N/AN/AN/AN/A-32.58%-30.14%N/ASPRYARS Pharmaceuticals$8M-$0.49N/AN/AN/A-42.74%-21.85%-15.88%N/ATGTXTG Therapeutics$23.38M$0.3776.0528.15N/A13.31%26.05%9.58%11/3/2025 (Estimated)TLXTelix Pharmaceuticals$32.93MN/A0.0022.96N/AN/AN/AN/A8/20/2025 (Estimated)Latest SPRY, TLX, TGTX, and NUVL EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/20/2025H1 2025TLXTelix Pharmaceuticals$0.2160N/AN/AN/A$316.69 millionN/A8/13/2025Q2 2025SPRYARS Pharmaceuticals-$0.41-$0.46-$0.05-$0.46$12.92 million$15.72 million8/7/2025Q2 2025NUVLNuvalent-$1.27-$1.31-$0.04-$1.39N/AN/A8/4/2025Q2 2025TGTXTG Therapeutics$0.32$0.17-$0.15$0.17$147.76 million$141.15 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthNUVLNuvalentN/AN/AN/AN/AN/ASPRYARS PharmaceuticalsN/AN/AN/AN/AN/ATGTXTG TherapeuticsN/AN/AN/AN/AN/ATLXTelix PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioNUVLNuvalentN/A13.5713.57SPRYARS Pharmaceuticals0.376.175.98TGTXTG Therapeutics0.893.862.96TLXTelix Pharmaceuticals0.992.782.66Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipNUVLNuvalent97.26%SPRYARS Pharmaceuticals68.16%TGTXTG Therapeutics58.58%TLXTelix PharmaceuticalsN/AInsider OwnershipCompanyInsider OwnershipNUVLNuvalent10.20%SPRYARS Pharmaceuticals33.50%TGTXTG Therapeutics10.64%TLXTelix PharmaceuticalsN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableNUVLNuvalent4072.11 million64.75 millionOptionableSPRYARS Pharmaceuticals9098.83 million65.72 millionOptionableTGTXTG Therapeutics290158.67 million141.78 millionOptionableTLXTelix PharmaceuticalsN/A338.40 millionN/AN/ASPRY, TLX, TGTX, and NUVL HeadlinesRecent News About These CompaniesTelix Pharmaceuticals Limited (TLX) Shares Fall Amid SEC Subpoena -- Hagens Berman2 hours ago | globenewswire.comTelix Pharmaceuticals (TLX) Expected to Announce Earnings on WednesdayAugust 18 at 2:38 AM | americanbankingnews.comTelix Pharmaceuticals (NASDAQ:TLX) Stock Price Up 4.3% - Should You Buy?August 17 at 1:19 PM | marketbeat.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Telix Pharmaceuticals Limited – TLXAugust 17 at 11:15 AM | globenewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Telix Pharmaceuticals Limited - TLXAugust 16, 2025 | prnewswire.comTelix Pharmaceuticals (NASDAQ:TLX) Sees Unusually-High Trading Volume - Here's What HappenedAugust 15, 2025 | marketbeat.comTelix Pharmaceuticals (TLX) Projected to Post Earnings on WednesdayAugust 14, 2025 | marketbeat.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Telix Pharmaceuticals Limited – TLXAugust 13, 2025 | globenewswire.comTelix Pharmaceuticals Limited (TLX) Shares Fall Amid SEC Subpoena – Hagens BermanAugust 12, 2025 | globenewswire.comTelix Pharmaceuticals (NASDAQ:TLX) Reaches New 1-Year Low - Time to Sell?August 12, 2025 | marketbeat.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Telix Pharmaceuticals Limited - TLXAugust 11, 2025 | prnewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Telix Pharmaceuticals Limited – TLXAugust 9, 2025 | globenewswire.comTelix Pharmaceuticals Limited (TLX) Shares Fall Amid SEC Subpoena -- Hagens BermanAugust 8, 2025 | globenewswire.comTelix Pharmaceuticals (NASDAQ:TLX) Sees Large Volume Increase - Time to Buy?August 7, 2025 | marketbeat.comABC Arbitrage SA Takes Position in Telix Pharmaceuticals Limited (NASDAQ:TLX)August 7, 2025 | marketbeat.comTelix Pharmaceuticals (NASDAQ:TLX) Shares Gap Down - Here's WhyAugust 6, 2025 | marketbeat.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Telix Pharmaceuticals Limited - TLXAugust 6, 2025 | prnewswire.comBroker says Telix shares could surge 80% higher after selloffAugust 5, 2025 | msn.comTelix Pharmaceuticals Limited (TLX) Shares Fall Amid SEC Subpoena -- Hagens BermanAugust 5, 2025 | globenewswire.comTelix Pharmaceuticals (NASDAQ:TLX) Reaches New 52-Week Low - Should You Sell?August 5, 2025 | marketbeat.comTLX Investors Have Opportunity to Join Telix Pharmaceuticals Limited Fraud Investigation with the Schall Law FirmJuly 31, 2025 | businesswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeSPRY, TLX, TGTX, and NUVL Company DescriptionsNuvalent NASDAQ:NUVL$73.28 -1.39 (-1.86%) As of 02:57 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Nuvalent, Inc., a clinical stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are NVL-520, a novel ROS1-selective inhibitor to address the clinical challenges of emergent treatment resistance, central nervous system (CNS)-related adverse events, and brain metastases that may limit the use of ROS1 tyrosine kinase inhibitors (TKIs) for patients with ROS proto-oncogene 1 (ROS1)-positive non-small cell lung cancer (NSCLC) which is under the phase 2 portion of the ARROS-1 Phase 1/2 clinical trial; NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, CNS-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under the phase 2 portion of the ALKOVE-1 Phase 1/2 clinical trial; and NVL-330, a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to treat tumors driven by HER2ex20, brain metastases, and avoiding treatment-limiting adverse events including due to off-target inhibition of wild-type EGFR, which is expected to initiate phase 1 trial. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.ARS Pharmaceuticals NASDAQ:SPRY$14.36 +0.57 (+4.13%) As of 02:57 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers. ARS Pharmaceuticals, Inc. was founded in 2015 and is headquartered in San Diego, California.TG Therapeutics NASDAQ:TGTX$28.15 +0.23 (+0.82%) As of 02:56 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Umbralisib, an oral inhibitor of PI3K-delta inhibitor for the treatment of adult patients with relapsed or refractory marginal zone lymphoma and follicular lymphoma; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; Rhizen Pharmaceuticals, S A. for the development and commercialization of umbralisib; Jiangsu Hengrui Medicine Co.; and Novimmune SA, as well as collaboration agreement with Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies. TG Therapeutics, Inc. was incorporated in 1993 and is based in Morrisville, North Carolina.Telix Pharmaceuticals NASDAQ:TLX$11.02 -0.28 (-2.48%) As of 02:57 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Telix Pharmaceuticals Limited. engages in the development and commercialization of several clinical-stage oncology assets. It operates through the following segments: Commercial, Product Development, and Group and Unallocated. The Commercial segment includes sales of Illuccix and other products subsequent to obtaining regulatory approvals. The Product Development segment develops radiopharmaceutical products for commercialization. It focuses on cancer care, specifically in prostate, renal or kidney and glioblastoma or brain cancer. Its products include TLX250, TLX591, and TLX101. The company was founded by Andreas Kluge and Christian P. Behrenbruch in November 2015 and is headquartered in Melbourne, Australia. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Archer's Flight Milestones & Defense Wins Excite Wall Street Home Depot Holds Gains After Narrow Q2 Misses 2 Powerful Forces Now Back Intel's Turnaround The Case for Buying NVIDIA Stock Ahead of the Robotics Surge Medtronic: The Opportunity Gets Healthier for Income Investors Palo Alto Networks Uptrend Confirmed! New Highs Set by Year’s End Micron Stock Still Cheap Despite 25% Rally, Analysts Say Qualcomm Just Passed 1 Major Test, But Can It Pass the Next? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access